Vildagliptin/metformin

Drug Profile

Vildagliptin/metformin

Alternative Names: Equmet; Eucreas; Galvumet; Galvus Met; Galvusmet; Icandra; LMF 237; Metformin/vildagliptin; Zomarist

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Hanmi Pharmaceutical; Novartis; UCB
  • Class Antihyperglycaemics; Biguanides; Cycloparaffins; Insulin sensitisers; Nitriles; Polycyclic bridged compounds; Pyrrolidines
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 27 Jan 2017 Novartis has patent protection for vildagliptin/metformin in Europe and Japan (Novartis 20-F filed in 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 29 Aug 2016 Launched for Type-2 diabetes mellitus in Bangladesh (PO) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top